DHA and ARA are fatty acids involved in normal development. Evaluating a formula claim requires a second question: what did a study actually show for children? The useful answer depends on the formula tested, the babies enrolled, the outcome measured, and the length of follow-up.
This is a guide to interpreting evidence and discussing a U.S. infant-formula choice. Premature infants and babies with medical conditions need an individualized feeding plan.
Separate a nutrient's role from a measured benefit
DHA means docosahexaenoic acid, a long-chain omega-3 fatty acid. ARA, also called AA, means arachidonic acid, an omega-6 fatty acid. Both occur in human milk and are studied in infant nutrition. DHA is a component of cell membranes and is concentrated in the brain and retina; the NIH Office of Dietary Supplements explains the fatty-acid background.
A developmental role supplies a reason to study a nutrient. A claim about better language, vision, school performance, or IQ requires a study of that particular outcome. Blood fatty-acid levels, an infant attention task, and an adolescent examination score answer different questions.
What selected trials and later analyses found
The examples below illustrate why a simple “more DHA means higher IQ” promise outruns the evidence. They are an evidence-reading guide, not a ranking of current products or an exhaustive systematic review.
On small screens, scroll horizontally or focus the table and use the arrow keys.
| Research | Reported finding | How to use it |
|---|---|---|
| 2013 DIAMOND follow-up | Among 81 re-enrolled children, investigators found advantages on some later cognitive tasks, but not every measure; standardized testing at 18 months showed no supplementation effect. | Age and test choice matter. A small follow-up does not establish a universal benefit for every child or formula. |
| 2021 school-record linkage | Seven earlier formula trials were linked to education records. The LCPUFA comparisons found no benefit on the primary mathematics outcome at age 16. | This is long-term evidence about the studied formulations and cohorts, not a test of every product now sold. |
| 2022 COGNIS follow-up | The experimental formula combined several ingredients, including fatty acids, milk-fat-globule-membrane components, and synbiotics; researchers examined cognition and brain structure at age six. | A combined intervention cannot isolate a DHA-only effect. The breastfeeding reference group was not randomized. |
| 2025 meta-analysis | Nine trials showed a small positive pooled cognitive effect, while the overall Bayley mental and psychomotor index comparisons were not statistically significant. | Read the outcome-specific results and study differences before translating a pooled finding into a label claim. |
The 2021 study also reported lower scores on some secondary school outcomes in its LCPUFA groups. That finding warrants careful follow-up; it does not demonstrate that a particular current formula harms an individual child. Conversely, a positive result on one test cannot promise a child's future academic performance.
Population matters as much as date. A 2026 trial analysis in very preterm infants studied supplemental AA and DHA and an MRI brain-volume outcome at term-equivalent age. It supplies a research question for neonatal care, not a dosing or shopping rule for a healthy term infant.
Use five questions when a headline sounds decisive
- Who was studied? Check gestational age, health needs, and whether the children resemble the population named in the claim.
- What actually changed? Was DHA the only difference, were DHA and ARA changed together, or did the formula contain several additional ingredients?
- What was compared? A randomized formula comparison supports different conclusions from a comparison with families who chose breastfeeding.
- Which result is being advertised? Look for the primary outcome, the age at testing, and whether other outcomes differed.
- How complete was follow-up? Check how many enrolled children were assessed, uncertainty around the result, funding, and whether other studies agree.
Compare quantities only when the units match
Record the exact product name, whether the number is for DHA alone or a combination, and the denominator. Milligrams per 100 kilocalories, milligrams per serving, and percentage of total fatty acids are different expressions. A number with a larger face value may represent a smaller concentration if its denominator differs.
Use the manufacturer's prepared-formula information when comparing products, and ask a clinician or dietitian to interpret unfamiliar units. A trial's concentration or a marketing comparison is not a personalized daily prescription. Do not alter the powder-to-water ratio or add oils or supplements to change a formula's DHA content.
Bring the evidence back to the feeding decision
CDC's selection guidance emphasizes iron-containing infant formula and the baby's needs. Ask your clinician whether there is a medical reason to choose a particular product, whether a proposed switch solves an actual problem, and how to evaluate growth and feeding tolerance.
For everyday handling, use the formula preparation and storage guide. Safe preparation, reliable access, and a feeding plan caregivers can follow belong in the decision alongside nutrient evidence.
Continue exploring
Explore baby care, feeding, and safety. Sources are linked beside the guidance they support. Updated October 11, 2026.